Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors
NCT ID: NCT06573294
Last Updated: 2025-12-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
45 participants
INTERVENTIONAL
2024-08-28
2027-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Trial details include:
* The trial duration for an individual participant will be up to approximately 11 months.
* The treatment duration for an individual participant will be up to approximately 4 months (the duration of treatment may vary for each participant) and the follow-up duration for an individual participant will be approximately 6 months.
Participation in the trial will require visits to the site. All participants will receive active drug; no one will be given placebo.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The dose escalation will evaluate different dose levels by assessing safety, tolerability, and early efficacy signals to determine the expansion dose(s) of GEN1057 as monotherapy, as well as characterizing the pharmacokinetic (PK) profile and immunogenicity in participants with malignant solid tumors who have metastatic or advanced disease.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GEN1057 Monotherapy
GEN1057
Intravenous (IV) infusion
Premedication
IV infusion/orally by mouth.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GEN1057
Intravenous (IV) infusion
Premedication
IV infusion/orally by mouth.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be at least 18 (or the legal age of consent in the jurisdiction in which the trial is taking place) years of age.
* Have measurable disease according to RECIST v1.1.
* Have Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1 at screening and on C1D1 pretreatment. Note: If screening ECOG PS is assessed within 3 days prior to C1D1, ECOG PS does not need to be reassessed at C1D1.
* Have a life expectancy of ≥3 months.
Exclusion Criteria
* Treatment with an investigational anticancer agent within 28 days or for systemic therapies within 5 half-lives of the drug, whichever is shorter, prior to trial treatment administration.
* Treatment with an investigational drug, including investigational vaccines within 28 days before the planned first dose of trial treatment.
* Prior treatment with live, attenuated vaccines within 28 days prior to initiation of GEN1057. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live, attenuated vaccines and are not allowed. Experimental and/or nonauthorized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations are not allowed.
* Used an invasive investigational medical device within 28 days before the planned first dose of trial treatment.
* Has clinically significant toxicities from previous anticancer therapies that have not resolved to baseline levels or to grade 1, except for anorexia, hyperthyroidism, hypothyroidism, and peripheral neuropathy, which must have recovered to ≤ grade 2. There is no limitation for alopecia and hearing impairment from previous therapies.
* Has known, symptomatic brain metastases. Asymptomatic brain metastases are allowed provided that they have been treated, have been stable for \>28 days as documented by radiographic imaging, and do not require prolonged (\>14 days) systemic corticosteroid therapy.
* Has a past or current malignancy other than inclusion diagnosis.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genmab
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Official
Role: STUDY_DIRECTOR
Genmab
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
SCRI Oncology Partners
Nashville, Tennessee, United States
South Texas Accelerated Research Therapeutics, LLC
San Antonio, Texas, United States
National Cancer Center, Tsukiji 5-1-1
Tokyo, , Japan
Hospital Universitari Vall d'Hebron
Barcelona, , Spain
Start Madrid Centro Integral Oncologico Clara Campal CIOCC
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-513563-75-00
Identifier Type: CTIS
Identifier Source: secondary_id
jRCT2031240508
Identifier Type: REGISTRY
Identifier Source: secondary_id
GCT1057-01
Identifier Type: -
Identifier Source: org_study_id